原发性胆汁性肝硬化的药物治疗  

Progress in the pharmacological treatment of primary biliary cirrhosis

作　　者：张福奎[1] 

机构地区：[1]首都医科大学附属北京友谊医院肝病中心,北京100050

出　　处：《临床药物治疗杂志》2012年第1期28-34,共7页Clinical Medication Journal

基　　金：北京市科技新星培养计划(项目编号:2006B54)

摘　　要：熊去氧胆酸是目前治疗原发性胆汁性肝硬化的唯一公认药物,可以改善早期患者的长期预后;对于熊去氧胆酸疗效不佳者迫切需要其他有效治疗药物治疗,但糖皮质激素、免疫抑制药或其他药物的疗效及安全性尚需更多的临床研究证实;终末期患者适合肝移植治疗。本文就原发性胆汁性肝硬化的药物治疗进展进行综述。The only established pharmacological therapy of primary biliary cirrhosis （PBC） is ursodeoxycholic acid （UDCA）, which could potentially improve long -term prognosis of the patients at early stages. However, alternative therapeutic approaches are urgently needed for patients responding insufficiently to UDCA, and more clinical studies are needed to confirm the safety and efficacy of glucocorticoids, immunosuppressants and other medicines. Liver transplantation is the option for end-stage patients. This paper is to review the progress in the pharmacological treatment of PBC.

关 键 词：肝硬化 胆汁性 熊去氧胆酸 糖皮质激素 

分 类 号：R575.2[医药卫生—消化系统] P9[医药卫生—内科学]